Prevention and treatment of hypergastrinemia

Details for Australian Patent Application No. 2003203632 (hide)

Owner Aphton Corporation

Inventors Michaeli, Dov; Gevas, Philip C.; Karr, Stephen; Watson, Susan; Grimes, Stephen

Agent Davies Collison Cave

Pub. Number AU-B-2003203632

Parent 40803

Filing date 10 April 2003

Wipo publication date 12 June 2003

Acceptance publication date 13 April 2006

International Classifications

A61K 39/385 (2006.01) Medicinal preparations containing antigens or antibodies - Haptens or antigens, bound to carriers

C07K 7/06 (2006.01) Peptides having 5 to 20 amino acids in a fully defined sequence

Event Publications

1 May 2003 Complete Application Filed

12 June 2003 Application Open to Public Inspection

  Published as AU-B-2003203632

13 April 2006 Application Accepted

  Published as AU-B-2003203632

30 November 2006 Standard Patent Sealed

13 September 2007 Assignment Registered

  Aphton Corporation The patent has been assigned to Receptor Biologix, Inc.

1 April 2010 Assignment Registered

  Receptor Biologix, Inc. The patent has been assigned to Cancer Advances, Inc.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003203633-Compositions and methods including formate brines for conformance control

2003203631-Identification of polynucleotides encoding novel heliobacter polypeptides in the helicobacter genome